Skip to content

NGM BIOPHARMACEUTICALS INC

CIK 0001426332

← back to feed
Revenue (TTM)
$12.16M
−92.0% YoY FY Mar 2024
Net Income (TTM)
−$161.97M
+12.5% YoY FY Mar 2024
EPS Diluted (TTM)
−$1.98
+14.8% YoY FY Mar 2024
Gross Margin
—
FY Mar 2024
Operating Margin
-1,398.5%
FY Mar 2024
Net Margin
-1,331.6%
FY Mar 2024
Free Cash Flow (TTM)
—
FY Mar 2024
Cash
$55.82M
FY Mar 2024
Total Debt
—
FY Mar 2024
Shares Outstanding
83.46M sh
FY Mar 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings